Search results for "Hypokalemia"

showing 10 items of 17 documents

Phase Ib Trial Trial of Rg7116, a Glycoengineered Monoclonal Antibody Targeting Her3, in Combination with Cetuximab or Erlotinib in Patients with Adv…

2014

ABSTRACT Aim: To evaluate the safety profile of RG7116 in combination with cetuximab or erlotinib. Methods: Patients (pts) with advanced or metastatic carcinomas with centrally confirmed HER3 protein expression were included. RG7116 plus cetuximab (400 mg/m2 followed by 250 mg/m2 qw IV) and RG7116 plus erlotinib (150 mg/day p.o.) combinations were evaluated in a dose escalation study with “3 + 3” design at a starting dose of 400 mg IV of RG7116 in a q2w regimen. Results: Twenty-seven pts were enrolled in 5 cohorts (400 to 2000 mg) in the cetuximab arm. One dose-limiting toxicity (DLT) of grade 3 dehydration was reported in the 800-mg cohort. Twenty-seven pts were enrolled in 4 cohorts (400 …

Oncologymedicine.medical_specialtyCetuximabbusiness.industryColorectal cancerHematologymedicine.diseaseRashHypokalemiaSurgeryRegimenOncologyInternal medicineMedicineErlotinibmedicine.symptombusinessOvarian cancerAdverse effectneoplasmsmedicine.drugAnnals of Oncology
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single cen…

2019

OBJECTIVE Despite limited evidence, electrical cardioversion of acute-onset atrial fibrillation (AAF) is widely performed in the emergency department (ED). The aim of this study was to describe the effectiveness and safety of electrical cardioversion of AAF performed by emergency physicians in the ED. METHODS All episodes of AAF electrically cardioverted in the ED were retrieved from the database for a 10-year period. Most patients not already receiving anticoagulants were given enoxaparin before the procedure (259/419). Procedural complications were recorded, and the patients were followed-up for 30 days for cardiovascular and hemorrhagic complications. RESULTS Four hundred nineteen eligib…

business.industryAtrial fibrillationEmergency departmentAtrial flutterEmergency Nursingmedicine.diseaseSingle CenterAtrial fibrillationHypokalemiaElectrical cardioversionAcute onsetEmergency service hospitalAnesthesiaEmergency MedicinemedicineHypertensive emergencyOriginal Articlemedicine.symptomElectric countershockbusinessAtrial flutterClinical and experimental emergency medicine
researchProduct

Hypokalemia shortens relative refractory period of peripheral sensory nerves in man

1977

Absolute and relative refractory periods and the sensory conduction velocity of the median and ulnar nerves were determined in six patients suffering from hypokalemia of various origins. Nerve impulse conduction and the absolute refractory period remained normal, but the relative refractory period was shortened to 1.7 to 2.6 ms at serum K+ levels from 1.6 to 2.9 mval/l. As compared with normal values this decrease was statistically significant.

medicine.medical_specialtyTime FactorsNeurologyRefractory Period ElectrophysiologicalRefractory periodbusiness.industryNeural ConductionHypokalemiaSensory systemNormal valuesNerve conduction velocityHypokalemiaPeripheralNeurologyRefractoryAnesthesiamedicineHumansPeripheral NervesNeurology (clinical)medicine.symptombusinessJournal of Neurology
researchProduct

Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality

2018

Background: The prognostic value of long-term potassium monitoring and dynamics in heart failure has not been characterized completely. We sought to determine the association between serum potassium values collected at follow-up with all-cause mortality in a prospective and consecutive cohort of patients discharged from a previous acute heart failure admission. Methods: Serum potassium was measured at every physician-patient encounter, including hospital admissions and ambulatory settings. The multivariable-adjusted association of serum potassium with mortality was assessed by using comprehensive state-of-the-art regression methods that can accommodate time-dependent exposure modeling. Res…

MaleHyperkalemiaPotassiumheart failure030204 cardiovascular system & hematology0302 clinical medicinecohort studiesCause of DeathRisk of mortalitylongitudinal studies030212 general & internal medicineProspective StudiesAged 80 and overpotassiumHazard ratioMiddle AgedPrognosisHypokalemiaCardiologyFemalemedicine.symptomCardiology and Cardiovascular Medicineacute heart failure; heart failure; hyperkalemia; hypokalemia; longitudinal cohort study; mortality; potassiumGlomerular Filtration RateRiskmedicine.medical_specialtyacute heart failurechemistry.chemical_elementHypokalemia03 medical and health sciencesPhysiology (medical)Internal medicinehypokalemiamedicineHumansIntensive care medicineAgedProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modellongitudinal cohort studyhyperkalemiamedicine.diseasemortalitySurvival AnalysisConfidence intervalchemistryHeart failurePotassiumPotentiometryHyperkalemiabusiness
researchProduct

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treat…

2017

Abstract Lessons Learned Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents. The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited efficacy in the patient population tested. Background KRAS-mutant tumors possess abnormal mitogen-activated protein kinases (MAPK) pathway signaling, leading to dysregulated cell proliferation. Cobimetinib blocks MAPK signaling. The dual-action antibody duligotuzumab (MEHD7945A) inhibits ligand binding to both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). Blockade of EGFR/HER3 and inhibitio…

Male0301 basic medicineOncologyMAPK/ERK pathwayCancer ResearchReceptor ErbB-3MAP Kinase Kinase 1Administration Oralmedicine.disease_causechemistry.chemical_compound0302 clinical medicinePiperidinesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesEpidermal growth factor receptor31biologyMiddle AgedErbB ReceptorsTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisFemaleDrug EruptionsKRASmedicine.symptomColorectal NeoplasmsSignal TransductionAdultmedicine.medical_specialty4HypokalemiaAcneiform eruptionProto-Oncogene Proteins p21(ras)03 medical and health sciencesAcneiform EruptionsInternal medicineHumansAdverse effectAgedNeoplasm StagingCobimetinibDose-Response Relationship Drugbusiness.industryClinical Trial Resultsmedicine.disease030104 developmental biologychemistryAstheniaImmunoglobulin Gbiology.proteinAzetidinesbusinessProgressive diseaseThe Oncologist
researchProduct

Monitoring and use of antimycotic (micafungin) for systemic use provided by the pharmacy of Marsala Hospital, Italy

2016

Micafungin is an antimycotic drug and represents an important addition to the available therapies for the treatment of systemic fungal infections. Micafungin is used: in the treatment of invasive candidiasis, oesophageal and prophylaxis of <em>Candida</em> infections. It inhibits, in a non-competitive way, the synthesis of 1,3-β-D-glucan, a component of fungal cell wall and is rapidly distributed into the tissues. It has a high-rate respectful bond with plasma protein, which is independent from the concentration of the drug. It is metabolized through the liver, being not subject to intense metabolic transformations until the excretion. There is no evidence of systemic accumulati…

medicine.medical_specialtyNauseaAnemiaPharmacyPlant SciencePharmacyGeneral Biochemistry Genetics and Molecular BiologyHypomagnesemiaExcretion03 medical and health sciencesHospital Pharmacy0302 clinical medicine030225 pediatricsInternal medicineIntensive caremedicineAntimycotic030212 general & internal medicineSicilylcsh:QH301-705.5Antimycotic; Micafungin; Hospital Pharmacybusiness.industryBiochemistry (medical)Micafunginmedicine.diseaseHypokalemiaSurgerylcsh:Biology (General)MicafunginSettore BIO/14 - Farmacologiamedicine.symptombusinessmedicine.drug
researchProduct

Renal involvement in psychological eating disorders

2011

Psychological eating disorders – anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder – are an increasing public health problem with severe clinical manifestations: hypothermia, hypotension, electrolyte imbalance, endocrine disorders and kidney failure; they are of interest to nephrologists, but pathophysiological mechanisms in determining the renal involvement are still unclear. We describe pathophysiology, histological features and clinical manifestations of the most frequent psychological eating disorders: AN and BN. Regarding AN, we analyze the recent literature, and identify 3 principal pathways towards renal involvement: chronic dehydration-hypokalemia, nephrocalcinosis …

MaleNephrologymedicine.medical_specialtyAnorexia NervosaHypokalemiaBioinformaticsRhabdomyolysisAdipokinesBinge-eating disorderInternal medicineAnimalsHumansMedicineObesityBulimiaInflammationDehydrationGlomerulosclerosis Focal Segmentalbusiness.industryBulimia nervosaBulimia Nervosa.Acute kidney injuryGeneral MedicineKidney diseasemedicine.diseaseKidney diseases; Anorexia Nervosa; Bulimia Nervosa.NephrocalcinosisEating disordersEndocrinologyNephrologyAnorexia nervosa (differential diagnoses)CytokinesIntercellular Signaling Peptides and ProteinsFemaleKidney DiseasesNephrocalcinosisbusinessKidney disease
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Hypokalemic rhabdomyolysis associated with Bartter's syndrome.

1983

Severe potassium deficiency is an uncommon cause of rhabdomyolysis. We recently treated a 45-year-old patient with myalgia, serious generalized weakness, increased serum creatine kinase and myoglobin level as well as excessive hypokalemia. Histological examination of deltoid muscle biopsy showed rhabdomyolysis. After complete recovery of muscle damage by potassium substitution Bartter's syndrome proved to be the cause of initial and persistent hypokalemia.

myalgiaMalemedicine.medical_specialtyendocrine system diseasesHypokalemiaurologic and male genital diseasesGastroenterologyNecrosisInternal medicineDeltoid muscleDrug DiscoveryBiopsyHyperaldosteronismmedicineHumansCreatine KinaseGenetics (clinical)Histological examinationmedicine.diagnostic_testbusiness.industryMyoglobinMusclesMyoglobinuriaBartter SyndromeGeneral MedicineMiddle Agedmedicine.diseaseHypokalemiaBartter's syndromeAnesthesiaPotassiumMolecular MedicinePotassium deficiencymedicine.symptombusinessRhabdomyolysisKlinische Wochenschrift
researchProduct